Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Receivables (2017 - 2022)

Summit Therapeutics filings provide 7 years of Receivables readings, the most recent being $349000.0 for Q4 2022.

  • Quarterly Receivables fell 82.88% to $349000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $349000.0 through Dec 2022, down 82.88% year-over-year, with the annual reading at $349000.0 for FY2022, 82.88% down from the prior year.
  • Receivables hit $349000.0 in Q4 2022 for Summit Therapeutics, up from $140000.0 in the prior quarter.
  • Across five years, Receivables topped out at $22.2 million in Q1 2019 and bottomed at $140000.0 in Q3 2022.
  • Average Receivables over 4 years is $6.0 million, with a median of $2.2 million recorded in 2021.
  • The largest annual shift saw Receivables tumbled 97.14% in 2020 before it skyrocketed 515.71% in 2021.
  • Summit Therapeutics' Receivables stood at $11.6 million in 2019, then tumbled by 97.14% to $331000.0 in 2020, then skyrocketed by 515.71% to $2.0 million in 2021, then tumbled by 82.88% to $349000.0 in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Receivables are $349000.0 (Q4 2022), $140000.0 (Q3 2022), and $1.3 million (Q2 2022).